## AMENDMENTS TO THE CLAIMS

## Listing of claims

This listing of the claims replaces all previous versions and listings of the claims in this application.

1. (Previously Presented) A tablet comprising a core containing an active substance and a compression coating surrounding the core,

wherein the core contains a colorant selected from the group consisting of titanium dioxide, calcium sulphate, magnesium oxide, aluminium silicate, aluminium hydroxide and iron oxide or an excipient that is opaque to x-rays such that when the tablet is exposed to penetrating radiation the core is contrasted with the coating and is visible through the coating.

- 2. (Previously Presented) The tablet according to claim 1 wherein the core contains a colorant that is red iron oxide.
- 3. (Cancelled).
- 4. (Previously Presented) The tablet according to claim 1 wherein the excipient is barium sulphate.
- 5. (Previously Presented) The tablet according to claim 1 wherein the colorant is present in amounts of 0.1% to about 1.75% by weight based on the total weight of the tablet.
- 6. (Previously Presented) The tablet according to claim 4 wherein the excipient is present in amounts of 0.1 to 2% based on the weight of the tablet.

Vergnault *et al.* USSN: 10/554,258

- 7. (Previously Presented) The tablet according to claim 1 wherein the active substance is a glucocorticosteroid selected from prednisone, prednisolone or methylprednisolone.
- 8. (Previously Presented) The tablet according to claim 1 in unit dosage form containing 1 or 5 mg prednisone.
- 9. (Previously Presented) A method of forming the tablet according to claim 1 comprising the step of compressing coating material in granulate powder form around the core.
- 10. (Currently Amended) [[The]]A use of a coloring agent or an excipient opaque to x-ray radiation in the core of a press-coated tablet comprising a core containing an active substance, and a coating surrounding said core, as a means for determining that the core is correctly located within the coating, wherein the coloring agent is selected from the group consisting of titanium dioxide, calcium sulphate, magnesium oxide, aluminium silicate, aluminium hydroxide and iron oxide.
- 11. (Previously Presented) A method of determining whether a core of a press-coated tablet is correctly located within a coating, comprising: preparing a press-coated tablet comprising a core containing an active substance and a coating surrounding the core wherein the core contains a colorant selected from the group consisting of titanium dioxide, calcium sulphate, magnesium oxide, aluminium silicate, aluminium hydroxide and iron oxide or an excipient that is opaque to x-rays.
- 12. (Previously Presented) The tablet according to claim 2 wherein the core contains an excipient that is opaque to x-rays.
- 13. (Previously Presented) The tablet according to claim 12 wherein the excipient is barium sulphate.

Vergnault *et al.* USSN: 10/554,258

- 14. (Previously Presented) The tablet according to claim 1 in unit dosage form containing 5 mg prednisone.
- 15. (New) The tablet according to claim 1, wherein the active substance is a sympathomimetic.
- 16. (New) The tablet according to claim 15, wherein the active substance is terbutaline sulphate.
- 17. (New) The tablet according to claim 15, wherein the active substance is present in amount of 0.1 to 50% based on weight of the core.